Here, we analyzed the expression levels of both progranulin and its receptor sortilin in a large and unique randomized clinical trial with long-term follow-up in order to clarify if tumor co-expression defined any specific breast cancer type in relation to clinical aggressiveness. Here, SORT1 is linked to breast cancer.